Patrinely JR, Johnson R, Lawless AR, et al. - This retrospective multicenter cohort study was run in the United States and Australia, to investigate the incidence, time course, spectrum, as well as links of chronic immune-related adverse events (irAEs) originating from adjuvant anti–PD-1 (programmed cell death 1) therapy for advanced melanoma. Participants were patients with stage III to IV melanomas managed with anti–PD-1 in the adjuvant setting. Development of a chronic irAE was seen in 43% of patients who received anti–PD-1 therapy, with only 14% resolving at last follow-up. Nonvisceral organs (endocrine, joints, salivary glands, eye, and peripheral nerves) were most commonly affected by chronic irAEs. It appeared that the observed chronic irAEs related to anti–PD-1 therapy in this study were more common when compared with that previously recognized and were shown to frequently persist even with prolonged follow-up, although most were low grade. Combining risks of chronic irAEs into treatment decision-making is recommended.